Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia

Cancer Genetics and Cytogenetics

Volumn 166, Issue 1, 2006, Pages 89-93

  Costa, Dolors ^a   Carrió, Ana ^a   Madrigal, Irene ^a   Arias, Amparo ^a   Valera, Alexandra ^a   Colomer, Dolors ^a   Aguilar, Josep Lluís ^a   Teixido, Montse ^b   Camós, Mireia ^a   Cervantes, Francisco ^a   Campo, Elías ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HYBRID PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CHROMOSOME 11Q; CHROMOSOME 12P; CHROMOSOME 12Q; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 5Q; CHROMOSOME ANALYSIS; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE DELETION; GENETIC VARIABILITY; HUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL;

ADULT; CHROMOSOME BANDING; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 9; CYTOGENETIC ANALYSIS; FEMALE; FUSION PROTEINS, BCR-ABL; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; TRANSLOCATION, GENETIC;

EID: 33645998789     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2005.08.024     Document Type: Article

References (17)

1. Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of Philadelphia-chromosome-positive chronic myeloid leukaemia. In: Chronic myeloproliferative disorders. Cytogenetic and molecular genetic abnormalities. Bain BJ, editor. Basel: S. Karger, 2002; pp. 44-61.
2. Mitelman F, Johansson B, Mertens F. Mitelman's database of chromosome aberrations in cancer. Available at: http://cgap.nci.nih.gov/Chromosomes/Mitelman. Accessed May 20, 2005.
3. Cohen N., Rozenfeld-Granot G., Hardan I., Brok-Simoni F., Amariglio N., Rechavi G., and Trakhtenbrot L. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 128 (2001) 114-119
4. Huntly B.J., Reid A.G., Bench A.J., Campbell L.J., Telford N., Shepherd P., Szer J., Prince H.M., Turner P., Grace C., Nacheva E.P., and Green A.R. Deletions of the derivative chromosome 9 occur at the same time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98 (2001) 1732-1738
5. Storlazzi C.T., Specchia G., Anelli L., Albano F., Pastore D., Zagaria A., Rocchi M., and Liso V. Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients. Genes Chromosomes Cancer 35 (2002) 271-276
6. Huntly B.J., Guilhot F., Reid A.G., Vassiliou G., Hennig E., Franke C., Byrne J., Brizard A., Niederwieser D., Freeman-Edward J., Cuthbert G., Bown N., Clark R.E., Nacheva E.P., Green A.R., and Deininger M.W. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 102 (2003) 2205-2212
7. Yoong Y., VanDeWalker T.J., Carlson R.O., Dewald G.W., and Tefferi A. Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia. Eur J Haematol 74 (2005) 124-127
8. Quintas-Cardama A., Kantarjian H., Talpaz M., O'Brien S., Garcia-Manero G., Verstovsek S., Rios M.B., Hayes K., Glassman A., Bekele B.N., Zhou X., and Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105 (2005) 2281-2286
9. In: Mitelman F. (Ed). ISCN (1995): An international system for human cytogenetic nomenclature (1995), S. Karger, Basel
10. Sinclair P.B., Nacheva E.P., Leversha M., Telford N., Chang J., Reid A., Bench A., Champion K., Huntly B., and Green A.R. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95 (2000) 738-743
11. Kalomietz E., Al-Maghrabi J., Brennan S., Karaskova J., Minkin S., Lipton J., and Squire J.A. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 97 (2001) 3581-3588
12. Aoun P., Wiggins M., Pickering D., Foran J., Rasheed H., Pavletic S.Z., and Sanger W. Interphase florescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis. Cancer Genet Cytogenet 154 (2004) 138-143
13. Reid A.G., Huntly B.J., Grace C., Green A.R., and Nacheva E.P. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol 121 (2003) 419-427
14. Fitzgerald P.H., and Morris C.M. Complex chromosomal translocations in the Philadelphia chromosome leukemias. Serial translocations or a concerted genomic rearrangement?. Cancer Genet Cytogenet 57 (1991) 143-151
15. Koduru P.R.K., Goh J.C., Pergolizzi R.G., Lichtman S.M., and Broome J.D. Molecular characterization of a variant Ph' translocation t(9;22;11)(q34;q11;q13) in chronic myelogenous leukemia (CML) reveals the translocation of the 3'-part of BCR gene to the chromosome band 11q13. Oncogene 8 (1993) 3239-3247
16. Yehuda O., Abeliovich D., Ben-Neriah S., Sverdlin I., Cohen R., Varadi G., Orr R., Ashkenazi Y.J., Heyd J., Lugassy G., and Ben Yehuda D. Clinical implications of fluorescence in situ hybridization analysis in 13 chronic myeloid leukemia cases: Ph-negative and variant Ph-positive. Cancer Genet Cytogenet 114 (1999) 100-107
17. Reddy K.S., and Sulcova V. A FISH study of variant Philadelphia rearrangements. Cancer Genet Cytogenet 118 (2000) 121-131